Caricamento...
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
Melanoma remains a critical public health problem worldwide. Patients with stage IV disease have very poor prognosis and their 1-year survival rate is only 25%. Until recently, systemic treatments with a positive impact on overall survival (OS) had remained elusive. In recent years, the United State...
Salvato in:
| Pubblicato in: | Cancer Med |
|---|---|
| Autore principale: | |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BlackWell Publishing Ltd
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4430259/ https://ncbi.nlm.nih.gov/pubmed/25619164 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.371 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|